Cerebroprotein Hydrolysate is a neurotrophic agent derived from porcine brain tissue. It is a complex mixture of low-molecular-weight peptides, amino acids, and nucleotides. In the Indian market, it is widely prescribed as a neuroprotective and neurorestorative agent for various neurological conditions. It is believed to support neuronal survival, enhance synaptic plasticity, and promote nerve growth factor (NGF) activity. It is administered via intramuscular injection or intravenous infusion.
Adult: 215.2mg once daily via intramuscular injection or slow intravenous infusion. For IV infusion, dilute in 100-250 mL of 0.9% Sodium Chloride Injection. The typical treatment course is 10-20 days, which may be repeated after a break of 2-4 weeks as per physician's advice.
Note: For IM use: Administer by deep intramuscular injection. Rotate injection sites. For IV use: Administer as a slow infusion over 60-90 minutes. Do not mix with other medications in the same syringe or infusion bag. Use immediately after reconstitution/dilution. Inspect solution for particulate matter or discoloration before use.
Cerebroprotein Hydrolysate exerts its effects through a multimodal mechanism. It contains biologically active peptides and amino acids that mimic endogenous neurotrophic factors. It is proposed to promote neuronal survival, stimulate neurite outgrowth, enhance synaptogenesis, and improve cerebral glucose utilization. It may modulate neurotransmitter systems, including cholinergic and monoaminergic pathways, and provide substrates for neuronal repair.
Pregnancy: Category C: Animal reproduction studies have not been conducted. It is not known whether Cerebroprotein Hydrolysate can cause fetal harm. Use only if the potential benefit justifies the potential risk to the fetus. Not recommended.
Driving: May cause dizziness or fatigue. Patients should be cautioned about operating machinery or driving until they know how the medication affects them.
| Anticoagulants (Warfarin, NOACs) | Theoretical risk of increased bleeding due to peptide content; monitor INR/clotting parameters. | Moderate |
| Antiepileptic Drugs | May potentially antagonize effects; monitor seizure control. | Moderate |
| CNS Depressants (Alcohol, Benzodiazepines) | Additive sedative effects possible; caution advised. | Mild |
Same composition (Cerebroprotein Hydrolysate (215.2mg)), different brands: